Drug profile · INN
camrelizumab
camrelizumab is a programmed cell death protein 1 antagonist.
Drug details — camrelizumab
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 19
- Data quality
- 0.70
Quick answer
camrelizumab is a programmed cell death protein 1 antagonist.
Key facts
Mechanism of action
Programmed cell death protein 1 antagonist
Primary target: Programmed cell death protein 1
Approval history
| Authority | Status | Date |
|---|---|---|
| NMPA | clinical trials | — |
Recent coverage
Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?
While many drugmakers are focused on lung cancer for PD-1/VEGF bispecifics, emerging evidence shows the liver may offer higher value. This analysis covers the mechanism, key players, and strategic implications for pharma teams.
NMPA Approval Lung Cancer Immunotherapy: PD-1/PD-L1 Combo Trends 2025
This article delves into the NMPA's approval landscape for lung cancer immunotherapy, highlighting the emerging trends of PD-1/PD-L1 combination therapies by 2025.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is camrelizumab?
camrelizumab is a programmed cell death protein 1 antagonist.